Overall, PIK3CA mutations appear to be present in 3–5% of patients with pancreatic cancer.20, 21, 22, 23 Though this is a small percentage, patients with this subtype of pancreatic cancer may be exquisitely sensitive to treatments targeting the PI3K pathway. Here, PIK3CA is linked to pancreatic neoplasm.